RLAY
Relay Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.01
+3.27%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$17.57
From 52W high−13.20%
Volume3.67M
Market cap$3.95B
P/E (TTM)—
P/S (TTM)381.3x
Div yield—
Key dataNov 4, 2026
Open
$17.57
From 52W high
−13.20%
Volume
3.67M
Market cap
$3.95B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−10.8x
P/E (TTM)
—
RSI (14)
45.6
MomentumView details →
1D Return
+3.27%
YTD Return
+108.05%
SummaryUpdated Jun 1, 2026
Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company founded in 2015 and headquartered in Cambridge, Massachusetts. Originally incorporated as Allostery, Inc., the company changed its name to Relay Therapeutics in December 2015 and went public in July 2020. Relay focuses on transforming drug discovery through computational approaches, with an emphasis on developing small molecule therapeutics for targeted oncology and genetic diseases.
Similar companies
Latest newsMore news →
Relay Therapeutics, Inc. said enrollment in its Phase 3 ReDiscover-2 trial in second-line breast cancer is expected to be completed in mid-2027.2h agoRelay Therapeutics, Inc. announced a second vascular-anomalies program involving a mutant-selective TIE2 inhibitor.2h agoRelay Therapeutics, Inc. appointed Shannon Campbell to lead commercial preparations for zovegalisib in breast cancer and vascular anomalies.2h ago